Drug Profile
Trastuzumab deruxtecan - AstraZeneca/Daiichi Sankyo
Alternative Names: DS 8201; DS 8201a; ENHERTU; Enhertu; fam-trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki; T-DXd; VRN-101099Latest Information Update: 09 Apr 2024
Price :
$50
*
At a glance
- Originator Daiichi Sankyo Company
- Developer AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Company; Medica Scientia Innovation Research; Seagen
- Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer; Gastric cancer; HER2 positive breast cancer; Non-small cell lung cancer
- Registered Solid tumours
- Phase II Adenocarcinoma; Biliary cancer; Colorectal cancer; Uterine cancer
- Phase I/II Urogenital cancer
Most Recent Events
- 06 Apr 2024 Registered for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)
- 18 Feb 2024 AstraZeneca initiates enrolment a phase II trial in Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in China (IV, Infusion) (NCT06271837)
- 13 Feb 2024 Daiichi Sankyo and AstraZeneca completes the DESTINY-Gastric02 phase II trial in Gastric cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA, Belgium, Italy, Spain and the UK (IV) (NCT04014075)